Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
Although tremendous advancements in cancer therapy over the last several years, cancer
still is a complex illness to cure. Traditional cancer treatments, including chemotherapy …
still is a complex illness to cure. Traditional cancer treatments, including chemotherapy …
[HTML][HTML] Cytokine release syndrome with chimeric antigen receptor T cell therapy
N Frey, D Porter - Biology of Blood and Marrow Transplantation, 2019 - Elsevier
Chimeric antigen receptor (CAR)-modified T cells (CAR-Ts) targeting CD19 have resulted in
unprecedented durable remissions for patients with relapsed and refractory B cell …
unprecedented durable remissions for patients with relapsed and refractory B cell …
Managing the toxicities of CAR T‐cell therapy
SS Neelapu - Hematological oncology, 2019 - Wiley Online Library
Chimeric antigen receptor (CAR) T‐cell therapy has the potential to revolutionize the
management of B‐cell lymphomas and possibly other cancers. Two anti‐CD19 CAR T‐cell …
management of B‐cell lymphomas and possibly other cancers. Two anti‐CD19 CAR T‐cell …
The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
Immune effector cells, including T cells and natural killer cells, which are genetically
engineered to express a chimeric antigen receptor (CAR), constitute a powerful new class of …
engineered to express a chimeric antigen receptor (CAR), constitute a powerful new class of …
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-
cell therapy have not been well studied. In an analysis of 83 patients with hematologic …
cell therapy have not been well studied. In an analysis of 83 patients with hematologic …